Guardant Health Investor Presentation slide image

Guardant Health Investor Presentation

Establishing a blood first paradigm in advanced cancer NILE Guardant360 FDA Approval Interim Readout 1H 2019 PMA Submission 1H 2019 <7-day TAT Pan-Cancer Medicare Coverage Post FDA Approval via the NGS NCD GUARDANTâ„¢
View entire presentation